Management of COVID-19 patients with chronic liver diseases and liver transplants.
Ann Hepatol
; 27(1): 100653, 2022.
Article
in English
| MEDLINE | ID: covidwho-1588313
ABSTRACT
The epidemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has increasingly attracted worldwide concern. Liver damage or dysfunction occurred in patients with COVID-19 (mainly characterized by moderately elevated serum aspartate aminotransferase levels). However, it is not yet clear whether the COVID-19-related liver injury is mainly caused by the virus infection, potentially hepatotoxic drugs, or other coexisting conditions. Progression of pre-existing chronic liver disease (CLD) may be the underlying mechanism of liver injury. Although COVID-19 patients with CLD, such as nonalcoholic fatty liver disease, liver cirrhosis, and liver cancer, have been deemed at increased risk for serious illness in many studies, little is known about the impact of CLD on the natural history and outcome of COVID-19 patients. Thereby, based on the latest evidence from case reports and case series, this paper discusses the clinical manifestations, treatment, prognosis, and management of the COVID-19 patients with different CLD. This article also reviews the effect of COVID-19 on liver transplantation patients (LT), hoping to work for future prevention, management, and control measures of COVID-19. However, due to the lack of relevant research, most of them are still limited to the theoretical stage, further study of COVID-19 and CLD needs to be improved in the future.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Liver Transplantation
/
Transplant Recipients
/
SARS-CoV-2
/
COVID-19
/
Liver Diseases
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Ann Hepatol
Journal subject:
Gastroenterology
Year:
2022
Document Type:
Article
Affiliation country:
J.aohep.2021.100653
Similar
MEDLINE
...
LILACS
LIS